Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Cancer Res. 2013 Feb 22;73(5):1547–1558. doi: 10.1158/0008-5472.CAN-12-3343

Figure 3.

Figure 3

Immuno-liposome delivery of anti-CD137 and IL-2Fc prevents lethal systemic inflammatory toxicity. A. Mice (n=4) were inoculated s.c. with B16F10 cells (5×104) and treated on day 9 with i.t. injection of soluble anti-CD137 + IL-2Fc or Lip-αCD137+Lip-IL-2Fc (100 μg antibody, 20 μg IL-2, “full dose”). Serum cytokine levels were measured on day 11 by Cytometric Bead Array. *p=0.003, **p=0.0003, ***p<0.0001. B. Average weight changes in tumor-bearing mice (n=7–11) treated intratumorally on days 9/12/16 (arrows) with saline, immuno-liposomes, or soluble αCD137+IL-2Fc (full or half-dose). Crosses denote treatment-related fatalities in the group receiving soluble therapy at full doses.